Nurix to present bexobrutideg CLL data at ASH meeting in December
Tweet Send to a Friend
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced it will present new and updated clinical data from its ongoing Phase 1a/1b study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




